ASH 2023 | Minimally invasive assessment of MRD in multiple myeloma

Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses the barriers to the use of measurable residual disease (MRD) in clinical practice, primarily the use of consequent bone marrow aspirates. As this is an invasive technique and not conducive to regular repeat testing in clinical practice, Dr Paiva emphasizes that the development of a minimally invasive technique for determining MRD status could facilitate more regular MRD testing in patients undergoing maintenance or who are under observation between treatments, transforming routine practice. A study of transplant-eligible and ineligible patients who were on maintenance or observation at the time of MRD assessment in the PETHEMA/GEM clinical trial (NCT00461747) evaluated MRD from peripheral blood, cfDNA and serum using various techniques. The results showed that MRD was detected with high sensitivity, highlighting the potential for minimally invasive MRD assessment in patients with multiple myeloma who are receiving maintenance therapy or are under observation. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.